HC Wainwright Lowers LAVA Therapeutics (NASDAQ:LVTX) Price Target to $2.00

LAVA Therapeutics (NASDAQ:LVTX) had its price target lowered by stock analysts at HC Wainwright from $6.00 to $2.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 102.24% from the company’s previous close.

A number of other analysts also recently weighed in on LVTX. Leerink Partners reiterated a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. JMP Securities restated a “market perform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.33.

LAVA Therapeutics Stock Performance

NASDAQ:LVTX opened at $0.99 on Friday. LAVA Therapeutics has a 52 week low of $0.96 and a 52 week high of $6.47. The firm’s fifty day moving average is $1.64 and its 200-day moving average is $1.79. The firm has a market cap of $25.07 million, a P/E ratio of -0.96 and a beta of 0.43.

Institutional Trading of LAVA Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pathway Financial Advisors LLC grew its stake in LAVA Therapeutics by 70.8% in the third quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after acquiring an additional 42,500 shares during the period. XTX Topco Ltd bought a new position in shares of LAVA Therapeutics in the 2nd quarter worth $55,000. Finally, Virtu Financial LLC acquired a new stake in LAVA Therapeutics in the 3rd quarter valued at $32,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.